

Curriculum Vitae

Personal information Sol Ruiz

Work experience

1. Employer: Institute of Health Carlos III, Madrid
 - Start date: 1998
 - End date: 2000
 - Position: Biotechnology Section Head
 - Activities:
 - Country: Spain
2. Employer: Spanish Medicines Agency
 - Start date: 2000
 - End date: 2008
 - Position: Biotechnology, Head of Service
 - Activities:
 - Country: Spain
3. Employer: European University of Madrid (UEM)
 - Start date: 012013
 - End date: 042013
 - Position: Instructor in Pharmaceutical Biotechnology
 - Activities:
 - Country: Spain
4. Employer: Spanish Medicines Agency
 - Start date: 2008
 - End date: 2015
 - Position: Biotechnology and Advanced Therapies, Head of Sector
 - Activities:
 - Country: Spain
5. Employer: Spanish Medicines Agency
 - Start date: 2015
 - End date:
 - Position: Head of Biologics, Biotechnology and Advanced Therapies
 - Activities:
 - Country: Spain

Education and training

1. Subject: Universidad Complutense Madrid (UCM)
 - Start date: 1982
 - End date: 1987
 - Qualification: BSc Science, Biology
 - Organisation: UCM
 - Country: Spain
2. Subject: Universidad Complutense Madrid (UCM)
 - Start date: 1988
 - End date: 1989
 - Qualification: MSc Biology
 - Organisation: UCM
 - Country: Spain
3. Subject: Fundación Jiménez Díaz (FJD), Madrid
 - Start date: 1991
 - End date: 1994
 - Qualification: PhD Immunology
 - Organisation: FJD
 - Country: Spain
4. Subject: University of California Irvine (UCI)
 - Start date: 1994
 - End date: 1997
 - Qualification: PhD Immunology
 - Organisation: UCI
 - Country: USA

Additional information

Publications

Ruiz, M.S., F. Carbonell, C. Platas, A. Padilla (1990). An enzyme-linked antiglobulin test for assessing anti-D immunoglobulin preparations. *Biologicals* 18: 89-95.

Marqués, G., L.C. Antón, E. Barrio, A. Sánchez, S. Ruiz, F. Gavilanes, F. Vivanco (1993). Arginine residues of the globular regions of human C1q involved in the interaction with immunoglobulin G. *Journal of Biological Chemistry* 268: 10393-10402.

Antón, L.C., S. Ruiz, G. Marqués, E. Barrio, A. Sánchez, F. Vivanco. (1994). C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates. *European Journal of Immunology* 24: 599-604.

Ruiz, S., A. Henschen_Edman, A.J. Tenner (1995). Localization of the site on the complement component C1q required for the stimulation of neutrophil superoxide production. *Journal of Biological Chemistry* 270: 30627-30634.

Nepomuceno, R.R., S. Ruiz, M. Park, A.J. Tenner (1999). C1qRP is a heavy O_glycosylated protein involved in the regulation of phagocytic activity. *Journal of Immunology* 162: 3583-3589.

Ruiz, S., A.H. Henschen_Edman, H. Nagase, A.J. Tenner (1999). Digestion of C1q collagen_like domain with matrix MMPs_1, _2, _3 and _9 further defines the sequence involved in the stimulation of neutrophil superoxide production. *Journal of Leukocyte Biology* 66: 416-421.

Ruiz, M.S. (1999). Biotechnological Products and Gene Therapy. What are we talking about? *Methods and Findings in Experimental and Clinical Pharmacology* 21, suppl.B: 7.

MA Serrano, S. Ruiz (2004): "Terapia Génica." Chapter 8 (Parte VII. Farmacología Clínica) of the book *Medicina Interna Vol. I y II*, 2ª Ed., J. Rodés, J. Guardia. Ed. Masson.

D.A. Fraser, S.S. Bohlson, N. Jasinskiene, N. Rawal, G. Palmarini, S. Ruiz, R. Rochford and A.J. Tenner (2006). C1q and MBL, components of the innate immune system, influence monocyte cytokine expression. *Journal of Leukocyte Biology* 80:107-116.

Timón M, Ruiz S. (2007). Bases regulatorias de los medicamentos de origen biotecnológico. *Revista Española de Economía de la Salud*. 2007; 6 (6): 346-351.

JS Robertson, J Blümel, K Brorson, A Gröner, TR Kreil, S Ruiz, H Willkommen (2009). Meeting report Virus & TSE safety forum 2008. *Biologicals* 37(5): 345-354.

The Committee for Advanced Therapies (CAT) (2010). Challenges with advanced therapy medicinal products and how to meet them. *Nature Reviews Drug Discovery* 9, 195-201.

Committee for Advanced Therapies and CAT Scientific Secretariat (2010). Use of unregulated stem_cell based medicinal products. *Lancet* 376(9740):514.

S Ruiz, F Abad_Santos (2010). Regulación y Evaluación de los ensayos clínicos de terapia celular. *Medicina clínica (Barc)* 135(1): 35-39.

S Ruiz, G Calvo (2011). Similar biological medicinal products: Lessons learned and challenges ahead. *Journal of Generic Medicines* 8: 4-13.

S Ruiz, E Sulleiro, G Calvo (2011). Medicamentos biotecnológicos: from dream to reality. *FAP* 9(3)

S Ruiz, A Gröner (2012). Pharmaceuticals. Chapter III.5 of the book *Decontamination of prions*. D Riesner, J_P Deslys, M Pocchiari and R Sommerville (Eds.). Dusseldorf University Press.

F Salmerón, A Portela, S Ruiz, M Timón, S López, R Hernaez, I Pérez, A. Sagredo (2012). La importancia de la regulación y el control de vacunas en la erradicación de enfermedades virales. Chapter of the book *Erradicación y control de las enfermedades producidas por virus*, R Nájera Morrondo (coordinador). Ed. Centro de estudios Ramón Areces.

CK Schneider, JJ Borg, F Ehmann, N Ekman, E Heinonen, K Ho, MH Hoefnagel, RM van der Plas, S Ruiz, AJ van der Stappen, R Thorpe, K Tiitso, AS Tsiftoglou, C Vleminckx, G Waxenecker, M Welin, M Weise, J_H Trouvin, BMWF & BWP (2012). In support of the European Union biosimilar framework. *Nature Biotechnology* 30: 745 – 748.

J Camarero, S Ruiz (2012). Cancer immunotherapy products: Regulatory aspects in the European Union. *Human Vaccines & Immunotherapeutics* 8:9, 1-6.

J Camarero, S Ruiz (2012). Immunotherapy in renal cell cancer: the more the merrier? (editorial). *Transl Androl Urol*

H Willkommen, J Blümel, K Brorson, D Chen, Q Chen, A Gröner, TR Kreil, JS Robertson, M Ruffing, and S Ruiz (2013). Meeting Report: PDA Virus and TSE Safety Forum. *PDA J Pharm Sci and Tech* 67: 81_97.

AS Tsiftoglou, S Ruiz, CK Schneider (2013). Development and Regulation of Biosimilars: Current Status and Future Challenges. *BioDrugs* 27 (3): 203-211.

Y López_Púa, S Ruiz, G Calvo (2013). Medicamentos biosimilares. Un concepto europeo exportado con éxito a todo el mundo. *BioPharmaceuticals* 2 (3): 20-30.

S. Ruiz (2014): "Normativa legal europea sobre medicamentos biosimilares", chapter of the book "Libro blanco de los medicamentos biosimilares en España: calidad sostenible", Fundación Gaspar Casal.

AS Tsiftoglou, JH Trouvin, G Calvo, S Ruiz (2014). Demonstration of Biosimilarity, Extrapolation of Indications and Other Challenges Related to Biosimilars in Europe. *BioDrugs* 28 (6): 479-486.

Salmikangas et al. (2015): Manufacturing, characterisation and control of cell_based medicinal products: challenging paradigms towards commercial use. *Regen Med* 10: 909-922.

A. Alonso_Gutiérrez, P. Díaz_Ramosa, E. Sulleiro_Avenidaño, M. de Miguel_Marañón, M.E. Padilla_Gallego, A. Sancho_López, S. Ruiz_Antúnez, C. Prieto_Yerro (2015). Contribución de la Agencia Española de Medicamentos y Productos Sanitarios al Comité Europeo de Evaluación de Medicamentos de Uso Humano. *Rev Clin Esp* 215(4): 230-235.

P Salmikangas, M Schuessler_Lenz, S Ruiz et al. (2015). Marketing regulatory oversight of advanced therapy medicinal products (ATMPs) in Europe: The EMA/CAT perspective; chapter in the book "Regulatory aspects of gene therapy and cell therapy products ". MC Galli and M Serabian (eds.). Springer Int Publ.

Willkommen H, Blümel J, Brorson K, Chen D, Chen Q, Gröner A, Kreil TR, Ruffing M, Ruiz S, Scott D, Silvester G (2016). Meeting Report: 2015 PDA Virus & TSE Safety Forum. *PDA J Pharm Sci Technol*. 70(2): 177-88.

S Ruiz (2017). Biosimilars in the EU: Regulatory Guidelines; chapter in the book "Biosimilar Drug Product Development". L Endrenyi, P Declerck and Shein_Chung Chow (eds.). CRC Press, Taylor & Francis Group.

FJ de Abajo, J Albanell, O Delgado Sanchez, K Klein, JV Moreno_Muelas, S Ruiz, MJ Sanz Ferrando, R Thorpe, F Zaragoza (2017). Roundtable on biosimilars: pharmacovigilance, traceability, immunogenicity 15 November 2016, Madrid, Spain. *GaBI J* 6 (1): 31-37.

Mark Cilia, Sol Ruiz, Peter Richardson, Tomas Salmonson, Anthony Serracino_Inglott, Francesca Wirth, and John Joseph Borg (2017). Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency's Committee for Medicinal Products for Human Use. *AAPS PharmSciTech* 18: 1_23. (https://doi.org/10.1208/s12249_017_0892_0)

S Ruiz (2018). Terapias avanzadas en patologías musculares, articulares e inmunológicas; chapter 5 in the book "Trastornos osteoarticulares, musculares e inmunológicos". Consejo General de Colegios Oficiales de Farmacéuticos (ed.).

S Ruiz (2019). Regulación de medicamentos de terapia avanzada en la Unión Europea. *PharmaTech* 41: 52-57. S Ruiz (2019).

Vector characterization & validation (interview). *Cell & Gene Therapy Insights* 2019; 5(4), 471–475

S Ruiz, M Timon (2019). Autorización de biosimilares en la Unión Europea. *El Médico* 1205: 8-11

A Portela, S Ruiz (2021). Evaluación y autorización de vacunas frente a la COVID_19. *RIECS* 2021, 6, 1; ISSN: 2530-2787

S Ruiz, I Moreno, D Pernas (2021). Retos y oportunidades de las terapias avanzadas. *Farmabiotec* 000: 46-47.

S Ruiz, I Moreno, D Pernas (2021). Medicamentos de terapia avanzada; ¿el futuro ya está aquí? Actualidad en Farmacología y Terapéutica (AFT) 19(4): 240-241

Martina Schuessler-Lenz, Carla Herberts, Ilona Reischl, Sol Ruiz, Patrick Celis, Claire Beuneu, Rune Kjekken, and Marcos Timón. (2023). Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe; chapter in the book "Regulatory Aspects of Gene Therapy and Cell Therapy Products - A Global Perspective" Second Edition. MC Galli (ed.). Springer Int Publ.

Falk Ehmann, Andreas Kuhn, Anna Maria Gerdina Pasmooij, Anthony Humphreys, Arjon Van Hengel, Brian Dooley, Brigitte Anliker, Camilla Svensson, Daniel Capaldi, David Henshall, Emer Cooke, Haiyan Zhou, Hilde Bastaerts, Jeske Smink, Joop Van Gerven, Leonor Enes, Lubomir Nechev, Marcel Hoefnagel, Mariëtte Driessens, Michael Wenger, Oriane Blanquie, Pawel Widomski, Ralf Herold, René Thürmer, Sol Ruiz, Steffen Thirstrup, Susan Goody, Tal Zaks, Valentina Cordò, and Annemieke M. Aartsma-Rus (2024). Report of the European Medicines Agency Conference on RNA-Based Medicines. *Nucleic Acid Ther.* 34(1): 4-11. doi: 10.1089/nat.2023.0021. Epub 2024 Jan 4. PMID: 38174996.

Olaghere, J., Williams, D. A., Farrar, J., Büning, H., Calhoun, C., Ho, T., Inamdar, M. S., Liu, D., Makani, J., Nyarko, K., Ruiz, S., Tisdale, J., McCune, J. M., Boadi, E., & Reagan-Udall Foundation for the FDA. (2025). Scientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence. *Biomedicine*, 13(3), 758.

Marcos Timón, Sol Ruiz (2025). Hospital Exemption for Advanced Therapy Medicinal Products in Spain. *Human Gene Therapy* 36: 17-18, 1095-1098

Projects

Memberships

Other Relevant Information

Chair of the Biologics Working Party (BWP) of the EMA (March 2014-February 2023), vice-chair of the BWP (September 2007-March 2014)

Co-opted member of the Committee for Human Medicinal Products (CHMP), EMA (September 2007-present)

Spanish/CHMP representative at the CAT (Committee for Advanced Therapies), EMA (January 2009-present)

Member of the ETF (Emergency Task Force, former COVID-19 EMA Pandemic Task Force), EMA (March 2022-present)

Chair of the VWP (Vaccines Working Party), EMA (May 2025-present)